Showing results (1691-1700 of 2,335) with videos related to

Sort By:
Pageof 234
American Journal of Respiratory Cell and Molecular Biology|December 8, 2015
Elevated MicroRNA-33 in Sarcoidosis and a Carbon Nanotube Model of Chronic Granulomatous DiseaseBarbara P Barna, Matthew McPeek, Anagha Malur, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2016
Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entityMyrella Vlenterie, Saskia Litière, Elisa Rizzo, et al.
JAMA|March 2, 1990
The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategiesM J Alter, S C Hadler, H S Margolis, et al.
Toxics|July 26, 2024
Using Zebrafish to Screen Developmental Toxicity of Per- and Polyfluoroalkyl Substances (PFAS)Katy N Britton, Richard S Judson, Bridgett N Hill, et al.
Primates; Journal of Primatology|September 1, 2023
Path To Acceptance and Refined Practices for Habituating Western Lowland GorillasProspère Teberd, Crickette Sanz, Alice Zambarda, et al.
JAMA Otolaryngology-- Head & Neck Surgery|June 7, 2014
Public awareness of head and neck cancers: a cross-sectional surveyAlexander L Luryi, Wendell G Yarbrough, Linda M Niccolai, et al.
Investigational New Drugs|August 5, 2010
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanomaSimon Pacey, Martin Gore, David Chao, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2005
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mgJohn R Zalcberg, Jaap Verweij, Paolo G Casali, et al.
Anti-Cancer Drugs|January 19, 2017
Pazopanib, a promising option for the treatment of aggressive fibromatosisZoltan Szucs, Christina Messiou, Han Hsi Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitorRuth Plummer, Charlotte Rees, Andrew Hughes, et al.
Pageof 234